Latest News for: ose
Edit
New Name to be Listed on the OSE Securities Options Market (Japan Exchange Group Inc)
Public Technologies 19 Mar 2026
Edit
10/03/2026 OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth (OSE Immunotherapeutics SA)
Public Technologies 10 Mar 2026
Edit
OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of ...
Nasdaq Globe Newswire 10 Mar 2026
OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth ... .
Edit
OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth
Pharmiweb 10 Mar 2026
Nantes, France, March 10, 2026 – 7.30am CET - OSE Immunotherapeutics SA (ISIN ... OSE), today announced the transition of Marc Le Bozec from interim to permanent Chief Executive Officer, effective immediately.
Edit
John Dwyer Shares Surprise New OSEES EP Cara Maluco, Damaged Bug Single “Over-Exposed”
Stereogum 06 Mar 2026
Edit
OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi®
Pharmiweb 03 Mar 2026
Nantes, France, March 2, 2026 – 6.00pm CET - OSE Immunotherapeutics SA (ISIN ... The Company will pause development of OSE‑230, allowing OSE to focus its resources on late‑stage, high‑potential assets lusvertikimab (OSE‑127) and Tedopi® ... OSE‑230.
Edit
OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi�
Nasdaq Globe Newswire 02 Mar 2026
Edit
Mowi ASA (OSE:MOWI): Board changes
Nasdaq Globe Newswire 27 Feb 2026
Ltd, and will be effective immediately. .
Edit
Mowi ASA (OSE:MOWI): Board changes (Mowi ASA)
Public Technologies 27 Feb 2026
). 27 Feb 2026 22.00 CET. Subscribe. Issuer. Mowi ASA. Today, on 27 February 2026, Ørjan Svanevik has resigned from his position as. Chair of the Board of Mowi ASA. The resignation as Chair of the Board is the ... an associated company of Geveran Trading Co.
Edit
OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer (OSE Immunotherapeutics SA)
Public Technologies 26 Feb 2026
Edit
OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial Evaluating Tedopi� in ...
Nasdaq Globe Newswire 26 Feb 2026
Edit
26/02/2026 OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer (OSE Immunotherapeutics SA)
Public Technologies 26 Feb 2026
Edit
OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer
Pharmiweb 26 Feb 2026
NANTES, France, February 26, 2026 – 6pm CET - OSE Immunotherapeutics SA (ISIN ... Silvia Comis, Chief Clinical and Medical Research Officer at OSE Immunotherapeutics, commented ... About OSE Immunotherapeutics ... www.ose-immuno.com.
Edit
Greece Launches railway APP: Real-Time Train Tracking Platform Boosts Safety Post-Tempi
Greek City Times 26 Feb 2026
....
Edit
The shares in Equinor ASA (OSE: EQNR; NYSE: EQNR) will as from today be traded on the New York Stock Exchange exclusive the third quarter 2025 cash dividend as detailed below (Form 6-K) (Equinor ASA)
Public Technologies 17 Feb 2026
). The shares in Equinor ASA (OSE. EQNR; NYSE ... Ex. date. 17 February 2026. Dividend amount. 0.37. Announced currency. USD ... Attachments Original document Permalink. Disclaimer.
- 1
- 2
- Next page »